Sil­i­con Val­ley Bank shut­ters; Rare dis­ease tri­als can't find enough pa­tients; FDA ad­comm votes in fa­vor of Po­livy la­bel ex­pan­sion; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

As a re­minder, we’re col­lect­ing nom­i­na­tions for our an­nu­al 20 un­der 40 and LGBTQ+ fea­tures. The dead­lines are March 23 and March 16, re­spec­tive­ly, so be sure to sub­mit your nom­i­na­tions!

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER